Adeno‐Associated Virus‐Induced Humanized Hypertensive Mouse Model Validates N‐Acetylgalactosamine‐Conjugated Small Interfering RNA Targeting Angiotensinogen as a Long‐Acting Antihypertensive Therapy
Journal of the American Heart Association · 12.11.2026
DOI: 10.1161/jaha.125.046444 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Heart Association, online erschienen am 12.11.2026. Verfasst von Junhao Xiong und 11 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Center for Systems Biomedicine, Department of Cardiovascular Surgery Shanghai…. Die Arbeit nennt 63 Literaturangaben.
Abstract (Originalsprache)
Background
Hypertension remains a leading cause of global morbidity and mortality, yet current therapeutic strategies lack sustained efficacy and long‐term stability. Our study aimed to construct a humanized rodent model for drugs development especially currently prevalent small interfering RNA medication.
Methods
A humanized hypertensive mouse model was generated by subcutaneous injection of neonatal mice with adeno‐associated viruses encoding hAGT (human angiotensinogen) and hRENIN (human renin). Blood pressure was monitored weekly via tail‐cuff plethysmography. Expression of hAGT and hRENIN was assessed by ELISA, Western blot, and reverse transcription quantitative polymerase chain reaction. Cardiac function was evaluated by echocardiography at 4 and 6 months postinjection. Hypertension‐associated comorbidities were examined through histological analysis and ELISA. A modified N‐acetylgalactosamine‐conjugated small interfering RNA targeting human hepatic AGT (GalNAc‐siAGT) was screened and subcutaneously administered to humanized hypertensive mice, either alone or in combination with valsartan, to evaluate therapeutic efficacy.
Results
The dual adeno‐associated virus‐induced humanized hypertensive model exhibited a sustained hypertension for 6 months and manifested prevalent comorbidities, including heart failure and kidney disease. This modified GalNAc‐siAGT demonstrated significant activity in knocking down hAGT both in vitro and in vivo. Only a single subcutaneous injection of GalNAc‐siAGT in humanized hypertensive mice led to a sustained reduction in blood pressure lasting for 2 months, accompanied by cardio‐ and renoprotective effects. Moreover, combining GalNAc‐siAGT with the renin‐angiotensin system blocker, valsartan, significantly enhanced therapeutic efficacy.
Conclusions
Our study validated the antihypertensive therapeutic effect of GalNAc‐siAGT in a humanized hypertensive murine model while highlighting the translational potential of this model for clinical drug development.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Center for Systems Biomedicine, Department of Cardiovascular Surgery Shanghai Chest Hospital Shanghai China.
- Department of Pediatric Cardiology, Engineering Research Center of Techniques and Instruments for Diagnosis and Treatment of Congenital Heart Disease, Xin Hua Hospital Shanghai Jiao Tong University Shanghai China.
- Basic Medical Research Center The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University Wenzhou Zhejiang China.
ORCID-Profile: Junhao Xiong, Xing Liu, Xiaoling Guo, Dan Zhu, Ruogu Li, Bing Zhang
Zitieren
APA
Xiong, J., Zhang, S., Cheng, K., Sheng, Y., Lin, J., Liu, X., Liu, T., Guo, X., Zhu, D., Wu, L., Li, R., & Zhang, B. (2026). Adeno‐Associated Virus‐Induced Humanized Hypertensive Mouse Model Validates N‐Acetylgalactosamine‐Conjugated Small Interfering RNA Targeting Angiotensinogen as a Long‐Acting Antihypertensive Therapy. Journal of the American Heart Association. https://doi.org/10.1161/jaha.125.046444
Vancouver
Xiong J, Zhang S, Cheng K, Sheng Y, Lin J, Liu X, et al. Adeno‐Associated Virus‐Induced Humanized Hypertensive Mouse Model Validates N‐Acetylgalactosamine‐Conjugated Small Interfering RNA Targeting Angiotensinogen as a Long‐Acting Antihypertensive Therapy. Journal of the American Heart Association. 2026. doi:10.1161/jaha.125.046444
BibTeX
@article{Xiong2026,
author = {Xiong, Junhao and Zhang, Shasha and Cheng, Kang and Sheng, Yuanzhe and Lin, Juntao and Liu, Xing and Liu, Tingting and Guo, Xiaoling and Zhu, Dan and Wu, Lianpin and Li, Ruogu and Zhang, Bing},
title = {Adeno‐Associated Virus‐Induced Humanized Hypertensive Mouse Model Validates N‐Acetylgalactosamine‐Conjugated Small Interfering RNA Targeting Angiotensinogen as a Long‐Acting Antihypertensive Therapy},
journal = {Journal of the American Heart Association},
year = {2026},
doi = {10.1161/jaha.125.046444}
}
EUVIMED